AAMS Infectious Diseases & Microbiology · Vol. 1 · Issue 4 · 2024-12-12
Tuberculosis Treatment Outcomes with Novel Bedaquiline-Based Regimens: A Phase III Trial
Ndlovu ZM, Mthembu S, Dlamini P
Department of Pulmonology, University of KwaZulu-Natal, Durban, South Africa¹; South African Medical Research Council, Cape Town, South Africa²
Abstract
Phase III randomized trial of 450 patients with drug-resistant tuberculosis demonstrates that bedaquiline-pretomanid-linezolid regimen achieves 90% culture conversion at 6 months with acceptable safety profile.
Keywords: Tuberculosis, Bedaquiline, Drug Resistance, Phase III Trial, Treatment Outcomes
Full Text
Phase III randomized trial of 450 patients with drug-resistant tuberculosis demonstrates that bedaquiline-pretomanid-linezolid regimen achieves 90% culture conversion at 6 months with acceptable safety profile.
This article is published open access by AAMS Infectious Diseases & Microbiology. The complete peer-reviewed text can be read on the journal page.
Author Citation Metrics
- Mthembu S — Citations: 47 · h-index: 4 · i10-index: 3 · ORCID 0009-0008-7516-7418
- Dlamini P — Citations: 71 · h-index: 1 · i10-index: 1
Metrics are sourced from public bibliometric records (OpenAlex) and each author's Google Scholar profile.